These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 773590

  • 1. Pharmacokinetics and hemodialyzability of cefazolin in uremic patients.
    Craig CP, Rifkin SI.
    Clin Pharmacol Ther; 1976 Jun; 19(6):825-9. PubMed ID: 773590
    [Abstract] [Full Text] [Related]

  • 2. Effects of renal failure and dialysis on cefazolin pharmacokinetics.
    Madhavan T, Yaremchuk K, Levin N, Fisher E, Cox F, Burch K, Haas E, Pohlod D, Quinn EL.
    Antimicrob Agents Chemother; 1975 Jul; 8(1):63-6. PubMed ID: 1164008
    [Abstract] [Full Text] [Related]

  • 3. Cefamandole kinetics in uremic patients undergoing hemodialysis.
    Gambertoglio JG, Aziz NS, Lin ET, Grausz H, Naughton JL, Benet LZ.
    Clin Pharmacol Ther; 1979 Nov; 26(5):592-9. PubMed ID: 498702
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis.
    Brogard JM, Pinget M, Brandt C, Lavillaureix J.
    J Clin Pharmacol; 1977 Apr; 17(4):225-30. PubMed ID: 849996
    [Abstract] [Full Text] [Related]

  • 5. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
    Polk RE, Kline BJ, Markowitz SM.
    Antimicrob Agents Chemother; 1981 Nov; 20(5):576-9. PubMed ID: 6459759
    [Abstract] [Full Text] [Related]

  • 6. Absorption, distribution and elimination of cefazolin in patients with normal renal function.
    Bergan T, Digranes A, Schreiner A.
    Chemotherapy; 1978 Nov; 24(5):277-82. PubMed ID: 352636
    [Abstract] [Full Text] [Related]

  • 7. Tissue levels of "cefazolin" in man after parenteral administration (author's transl).
    Cimmino PT, Garaci E.
    Antibiotica; 1973 Mar; 11(1):31-44. PubMed ID: 4619551
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of cefazolin patients with normal and impaired renal function.
    Bergan T, Brodwall EK, Orjavik O.
    J Antimicrob Chemother; 1977 Sep; 3(5):435-43. PubMed ID: 903324
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of cefazolin, a new cephalosporin antibiotic, in normal and uraemic patients.
    Leroy A, Canonne MA, Fillastre JP, Humbert G.
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):878-89. PubMed ID: 4214662
    [No Abstract] [Full Text] [Related]

  • 10. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin.
    Pabst J, Leopold G, Ungethüm W, Dingeldein E.
    Arzneimittelforschung; 1979 Sep; 29(2a):437-43. PubMed ID: 582722
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
    Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH.
    Antimicrob Agents Chemother; 1979 Nov; 16(5):615-21. PubMed ID: 526003
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.
    Kirby WM, De Maine JB, Serrill WS.
    Postgrad Med J; 1971 Feb; 47():Suppl:41-6. PubMed ID: 5556189
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of cephalosporins in patients with normal or reduced renal function.
    Andriole VT.
    J Infect Dis; 1978 May; 137 Suppl():S88-S99. PubMed ID: 349098
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans.
    Thys JP, Vanderkelen B, Klastersky J.
    Antimicrob Agents Chemother; 1976 Sep; 10(3):395-8. PubMed ID: 984782
    [Abstract] [Full Text] [Related]

  • 15. Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.
    Bergan T.
    Chemotherapy; 1977 Sep; 23(6):389-404. PubMed ID: 923329
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
    Philipson A, Stiernstedt G, Ehrnebo M.
    Clin Pharmacokinet; 1987 Feb; 12(2):136-44. PubMed ID: 3829560
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of cefazolin in normal and uremic subjects.
    Welling PG, Craig WA, Gordon AL, Kunin CM.
    Clin Pharmacol Ther; 1974 Apr; 15(4):344-53. PubMed ID: 4821438
    [No Abstract] [Full Text] [Related]

  • 18. Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: cefazolin.
    Lode H, Gebert S, Hendrischk A.
    Chemotherapy; 1975 Apr; 21(1):19-32. PubMed ID: 1097207
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans.
    Rattie ES, Ravin LJ.
    Antimicrob Agents Chemother; 1975 May; 7(5):606-13. PubMed ID: 1147591
    [Abstract] [Full Text] [Related]

  • 20. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.
    Scheld WM, Spyker DA, Donowitz GR, Bolton WK, Sande MA.
    Antimicrob Agents Chemother; 1981 Apr; 19(4):613-9. PubMed ID: 6454387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.